A phase III trial of 1,298 colorectal cancer patients has found that a combination of the drugs cetuximab (Erbitux) and irinotecan showed a significant improvement in progression-free survival over just irinotecan alone, according to an international team of researchers.
There is a new angle of attack on body acne in places that are hard-to-reach and treat, such as the back. ClindaReach?, a revolutionary easy to use treatment that packages a topical antibiotic with an ergonomically designed applicator to treat hard-to-reach acne, was launched this week by DUSA Pharmaceuticals, Inc. (NASDAQ GM: DUSA).
The U.S. Food & Drug Administration (FDA) is launching a special Web page to warn consumers about the dangers of buying isotretinoin (Accutane) online.
Understanding the link between Polycystic Ovary Syndrome (PCOS) and insulin resistance is the aim of a new project announced today, funded by the charity WellBeing of Women.
The largest study ever conducted on acne and stress reveals that teenagers who were under high levels of stress were 23 percent more likely to have increased acne severity, according to researchers from Wake Forest University School of Medicine and colleagues.
A study involving eight patients suggests that multiple low-energy treatments with a plasma skin regeneration tool may help to reduce wrinkles and improve facial appearance with minimal healing time, according to an article in the February issue of Archives of Dermatology, one of the JAMA/Archives journals. The multiple treatments have about the same effect as one high-energy session but with less healing time.
Three new studies by a University at Buffalo psychologist offer the first known evidence that some people anxiously expect that they will be rejected by others because of their physical appearance, and that this sensitivity, if not mitigated, has serious implications for their mental and physical health.
Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that a single once-daily morning dose of the investigational amphetamine compound SPD465, extended release triple-bead mixed amphetamine salts, designed to reduce symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults for up to 16 hours, was bioequivalent to a dose of ADDERALL XR (mixed salts of a single-entity amphetamine product) followed by a dose of mixed amphetamine salts immediate release (“MAS IR”) eight hours later.
QLT Inc. (NASDAQ: QLTI; TSX: QLT) today announced positive results of a Phase IV clinical trial of Aczone? in more than 50 patients with G6PD deficiency that was performed to meet a post-approval commitment requested by the FDA. The purpose of this study was to gather more information about the safety of Aczone, a prescription topical medicine, in treating patients with acne who have certain blood disorders.
About a third of patients who took the anti-acne drug Accutane developed elevated cholesterol levels, and over 40 percent showed raised levels of blood fats called triglycerides, a new report warns.